A method of performing a chemical reaction includes reacting a compound selected from the group consisting of an organohalide and an organo-pseudohalide, and a protected organoboronic acid represented by formula (I) in a reaction mixture:
R.sup.1—B-T  (I);
where R.sup.1 represents an organic group, T represents a conformationally rigid protecting group, and B represents boron having sp.sup.3 hybridization. When unprotected, the corresponding organoboronic acid is unstable by the boronic acid neat stability test. The reaction mixture further includes a base having a pK.sub.B of at least 1 and a palladium catalyst. The method further includes forming a cross-coupled product in the reaction mixture.

Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, the compounds disclosed herein are ENPP-1 inhibitors, pharmaceutical compositions, and methods for the treatment of cancer or a viral infection.

Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, the compounds disclosed herein are ENPP-1 inhibitors, pharmaceutical compositions, and methods for the treatment of cancer or a viral infection.

Provided are the following compound represented by General Formula (A) or (B), a curable resin composition including the compound, a cured product thereof, an optical member, and a lens:

##STR00001##

A ring Ar.sup.1 and a ring Ar.sup.2 represent an aromatic ring represented by a specific formula or a fused ring thereof, R.sup.1 and R.sup.2 represent a specific substituent, and v and w are a specific integer. R.sup.3 and R.sup.4 represent a hydrogen atom or a monovalent substituent, L.sup.1 and L.sup.2 represent an alkylene group having 1 to 6 carbon atoms, and Sp.sup.a to Sp.sup.d represent a single bond or a divalent linking group. Pol.sup.1 and Pol.sup.2 represent a hydrogen atom or a polymerizable group, in which at least one of Pol.sup.1 or Pol.sup.2 is a polymerizable group. Further, in the formulae, a structure represented by (R.sup.1).sub.v—Ar.sup.1/cyclopentadiene skeleton/Ar.sup.2—(R.sup.2).sub.w is not line-symmetrical.

Provided are the following compound represented by General Formula (A) or (B), a curable resin composition including the compound, a cured product thereof, an optical member, and a lens:

##STR00001##

A ring Ar.sup.1 and a ring Ar.sup.2 represent an aromatic ring represented by a specific formula or a fused ring thereof, R.sup.1 and R.sup.2 represent a specific substituent, and v and w are a specific integer. R.sup.3 and R.sup.4 represent a hydrogen atom or a monovalent substituent, L.sup.1 and L.sup.2 represent an alkylene group having 1 to 6 carbon atoms, and Sp.sup.a to Sp.sup.d represent a single bond or a divalent linking group. Pol.sup.1 and Pol.sup.2 represent a hydrogen atom or a polymerizable group, in which at least one of Pol.sup.1 or Pol.sup.2 is a polymerizable group. Further, in the formulae, a structure represented by (R.sup.1).sub.v—Ar.sup.1/cyclopentadiene skeleton/Ar.sup.2—(R.sup.2).sub.w is not line-symmetrical.

The present disclosure belongs to the technical field of organic materials, and provides an organic compound. An adamantane spirofluorenyl and an anthryl are connected to obtain a novel compound for an organic electroluminescence device. In this compound, adamantane in the adamantane spirofluorene greatly increases the density of electron clouds on the fluorenyl through the hyperconjugation effect, which reduces the HOMO energy level of the compound and improves the hole migration ability. Both the adamantane spirofluorene and the anthryl have high hole mobility, so when the two are connected, the overall hole mobility of molecules is further improved, which is beneficial to reducing the working voltage of the device and improving the luminous efficiency. The present disclosure further provides an electronic component and an electronic apparatus including the compound. The organic compound can improve the performance of the electronic component.

The present disclosure belongs to the technical field of organic materials, and provides an organic compound. An adamantane spirofluorenyl and an anthryl are connected to obtain a novel compound for an organic electroluminescence device. In this compound, adamantane in the adamantane spirofluorene greatly increases the density of electron clouds on the fluorenyl through the hyperconjugation effect, which reduces the HOMO energy level of the compound and improves the hole migration ability. Both the adamantane spirofluorene and the anthryl have high hole mobility, so when the two are connected, the overall hole mobility of molecules is further improved, which is beneficial to reducing the working voltage of the device and improving the luminous efficiency. The present disclosure further provides an electronic component and an electronic apparatus including the compound. The organic compound can improve the performance of the electronic component.

The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role. The compounds and pharmaceutical compositions described herein are also useful in the treatment of a condition, disorder or disease that is characterised by oxidative stress or where oxidative stress is likely to play or plays a substantial role; and/or a condition, disorder or disease that is characterised by activation of (1) one or more components of the necrosome; (2) death domain receptors; and/or (3) Toll-like receptors; and/or (4) players in ferroptotic/ferroptosis signalling, or where activation of any one of (1) to (3) and/or (4) is likely to play or plays a substantial role.

The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role. The compounds and pharmaceutical compositions described herein are also useful in the treatment of a condition, disorder or disease that is characterised by oxidative stress or where oxidative stress is likely to play or plays a substantial role; and/or a condition, disorder or disease that is characterised by activation of (1) one or more components of the necrosome; (2) death domain receptors; and/or (3) Toll-like receptors; and/or (4) players in ferroptotic/ferroptosis signalling, or where activation of any one of (1) to (3) and/or (4) is likely to play or plays a substantial role.

The invention provides methods of treating a bacterial infection in a mammal comprising administering to the mammal a substituted bicyclic heteroaromatic ring compound of formula I: wherein two of X.sub.1 to X.sub.8 are N and the remaining of X.sub.1 to X.sub.8 are CH; or a pharmaceutically acceptable salt thereof, as well as novel compounds of formula I and salts thereof and pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof. ##STR00001##